Literature DB >> 20308309

Immunotherapy for glioblastoma: a long and winding road.

Michael Weller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20308309      PMCID： PMC2940607          DOI： 10.1093/neuonc/noq027

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  4 in total

1.  Intra-tumoral dendritic cells increase efficacy of peripheral vaccination by modulation of glioma microenvironment.

Authors:  Serena Pellegatta; Pietro Luigi Poliani; Elena Stucchi; Daniela Corno; Chiara Agnese Colombo; Francesca Orzan; Maria Ravanini; Gaetano Finocchiaro
Journal:  Neuro Oncol       Date:  2010-01-06       Impact factor: 12.300

2.  Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study.

Authors:  Alexandre Carpentier; Philippe Metellus; Renata Ursu; Sarah Zohar; Francois Lafitte; Maryline Barrié; Yuxia Meng; Margaretha Richard; Christophe Parizot; Florence Laigle-Donadey; Guy Gorochov; Dimitri Psimaras; Marc Sanson; Annick Tibi; Olivier Chinot; Antoine F Carpentier
Journal:  Neuro Oncol       Date:  2010-01-25       Impact factor: 12.300

3.  Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties.

Authors:  Jennifer C Rodrigues; Guido C Gonzalez; Lei Zhang; George Ibrahim; John J Kelly; Michael P Gustafson; Yi Lin; Allan B Dietz; Peter A Forsyth; V Wee Yong; Ian F Parney
Journal:  Neuro Oncol       Date:  2009-12-22       Impact factor: 12.300

Review 4.  The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients.

Authors:  Amy B Heimberger; John H Sampson
Journal:  Expert Opin Biol Ther       Date:  2009-08       Impact factor: 4.388
  4 in total
  2 in total

1.  Natural killer cells require monocytic Gr-1(+)/CD11b(+) myeloid cells to eradicate orthotopically engrafted glioma cells.

Authors:  Gregory J Baker; Peter Chockley; Daniel Zamler; Maria G Castro; Pedro R Lowenstein
Journal:  Oncoimmunology       Date:  2016-03-16       Impact factor: 8.110

2.  Inhibition of NF-κB Pathway and Modulation of MAPK Signaling Pathways in Glioblastoma and Implications for Lovastatin and Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) Combination Therapy.

Authors:  Pi Chu Liu; Gang Lu; Yi Deng; Cheng Dong Wang; Xian Wei Su; Jing Ye Zhou; Tat Ming Chan; Xiang Hu; Wai Sang Poon
Journal:  PLoS One       Date:  2017-01-30       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.